Core Viewpoint - The company faces multiple types of mandatory delisting risks due to its stock price and financial performance issues [1] Financial Performance - As of January 16, 2026, the company's stock closed at 0.54 CNY per share, remaining below 1 CNY for 12 consecutive days, with a market capitalization of 189 million CNY, and below 300 million CNY for 6 consecutive days, potentially triggering trading-related mandatory delisting [1] - The estimated net asset for the fiscal year 2025 is expected to be negative, which, if audited as negative or if the financial report receives a non-standard opinion, will trigger financial-related mandatory delisting [1] Financial Irregularities - The financial reports from 2021 to 2023 contain false records, inflating revenues by 215.32 million CNY, 283.74 million CNY, and 233.63 million CNY, which may lead to mandatory delisting due to significant legal violations [1] Legal and Debt Risks - The company is also facing risks related to lawsuits and liabilities, adding to its overall financial instability [1]
*ST长药：股票面临多类强制退市风险
Xin Lang Cai Jing·2026-01-18 07:43